SNM's Nanomedicine and Molecular Imaging Summit wrapped up today in Albuquerque, N.M., with in-depth discussionand a high sense of energy looking ahead.
Nanotechnology is a quickly growing, but still-evolving field with nearly limitless possibilities for applying technology in highly targeted ways. For the medical community, nanotechnology involves using nanoparticles to target diseaseand treat many common and devastating diseases before they spread. Concomitantly, molecular imaging can be used to assess the health and environmental impacts of nanomaterials.
"Nanotechnology has the potential to revolutionize the way in which many common diseases are diagnosed and treated," said Peter S. Conti, M.D., Ph.D., professor of radiology at USC's Keck School of Medicine. "There are issues that need to be resolved, however, in order to make this technology clinically relevant. SNM's Molecular Imaging Center of Excellence summits serve a key role in the community by bringing together the appropriate experts to explore all facets of an issue."
Nanotechnology: Providing a Regulatory Framework in the U.S.
As part of the summit, advisors from the U.S. Food and Drug Administration (FDA) provided a regulatory framework for developing nanotechnology and targeted radiopharmaceuticals.
"FDA is pleased to work with SNM, physicians and other members of the molecular imaging community on the critical field of nanotechnology, which is evolving at a rapid pace as new technologies make these developments possible," said Wendy Sanhai, Ph.D., M.B.A., senior scientific advisor in the Office of the Commissioner at FDA.
Working in concert with SNM and other stakeholders, FDA is seeking to educate imaging physicians, researchers and other stakeholders about the regulatory requirements for novel techniques and regulatory pathways. Dr. Sanhai's discussion, presented at a session on regulatory considerations, focused on ways to advance
|Contact: Amy Shaw|
Society of Nuclear Medicine